1. Home
  2. OKLO vs SRRK Comparison

OKLO vs SRRK Comparison

Compare OKLO & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OKLO
  • SRRK
  • Stock Information
  • Founded
  • OKLO 2013
  • SRRK 2012
  • Country
  • OKLO United States
  • SRRK United States
  • Employees
  • OKLO N/A
  • SRRK N/A
  • Industry
  • OKLO
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • OKLO
  • SRRK Health Care
  • Exchange
  • OKLO NYSE
  • SRRK Nasdaq
  • Market Cap
  • OKLO 4.0B
  • SRRK 4.2B
  • IPO Year
  • OKLO N/A
  • SRRK 2018
  • Fundamental
  • Price
  • OKLO $31.32
  • SRRK $44.88
  • Analyst Decision
  • OKLO Buy
  • SRRK Strong Buy
  • Analyst Count
  • OKLO 3
  • SRRK 7
  • Target Price
  • OKLO $22.33
  • SRRK $40.43
  • AVG Volume (30 Days)
  • OKLO 15.2M
  • SRRK 985.1K
  • Earning Date
  • OKLO 02-13-2025
  • SRRK 11-12-2024
  • Dividend Yield
  • OKLO N/A
  • SRRK N/A
  • EPS Growth
  • OKLO N/A
  • SRRK N/A
  • EPS
  • OKLO N/A
  • SRRK N/A
  • Revenue
  • OKLO N/A
  • SRRK N/A
  • Revenue This Year
  • OKLO N/A
  • SRRK N/A
  • Revenue Next Year
  • OKLO N/A
  • SRRK N/A
  • P/E Ratio
  • OKLO N/A
  • SRRK N/A
  • Revenue Growth
  • OKLO N/A
  • SRRK N/A
  • 52 Week Low
  • OKLO $5.35
  • SRRK $6.76
  • 52 Week High
  • OKLO $31.91
  • SRRK $46.19
  • Technical
  • Relative Strength Index (RSI)
  • OKLO 66.48
  • SRRK 58.65
  • Support Level
  • OKLO $23.09
  • SRRK $42.74
  • Resistance Level
  • OKLO $26.49
  • SRRK $45.15
  • Average True Range (ATR)
  • OKLO 3.22
  • SRRK 2.39
  • MACD
  • OKLO 0.30
  • SRRK -0.24
  • Stochastic Oscillator
  • OKLO 94.92
  • SRRK 83.13

About OKLO OKLO INC

Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Share on Social Networks: